NCT06655519尚未招募1 期
An Exploratory Study of Fully Human Anti-B-Cell Maturation Antigen (BCMA)/G Protein-coupled Receptor, Class C Group 5 Member (GPRC5D) Chimeric Antigen Receptor T Cells (RD140) in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 12
- 主要终点
- Adverse Events
研究概览
简要总结
This is a single-center, open clinical study, divided into two phases of dose escalation and dose expansion, to observe the safety and efficacy of RD140 injection at different doses in patients with relapsed/refractory multiple myeloma or plasmacytic leukemia.
详细描述
This study is divided into two stages: dose escalation and dose extension. The "3+3" dose escalation design was adopted in the dose escalation stage, and three dose escalation dose groups of 1.0×10^5 CART(Chimeric Antigen Receptor T Cell) cells/kg, 3.0×10^5 CART cells/kg and 6.0×10^5 CART cells/kg were preset. Each dose group level included 3-6 subjects with a single dose. The objective is to preliminarily observe the safety and tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of RD140 injection at different doses in patients with relapsed/refractory multiple myeloma (RRMM) or plasma cell leukemia, and provide evidence for dose expansion phase.
In the dose expansion phase, 1 to 2 dose groups were selected for expansion based on the dose escalation phase, and 3 to 6 subjects were included in each extended dose group to further evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of RD140 injection in the treatment of RRMM or plasma cell leukemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 to 75 years old, male or female;
- •Diagnosed as Multiple Myeloma (MM) according to the international standard for multiple myeloma (IMWG), or diagnosed as primary plasma cell leukemia;
- •Subjects have had at least 3 prior lines of therapy including at least one proteasome inhibitor (PI), one immunomodulatory agent (IMiD), and one anti-CD38 monoclonal antibody, or subjects who were refractory to the above treatments.
- •Disease progression must be documented during or within 12 months following the most recent anti-tumor treatment (the progression for subjects whose last line treatment was CAR-T therapy was not limited to 12 months post-treatment);
- •Presence of measurable lesion at screening as determined by any of the following criteria for subjects with MM:
- •Serum M protein level: IgG type M protein ≥ 10 g/L, or IgA, IgD, IgE, IgM type M protein ≥ 5 g/L;
- •Urine M protein level ≥ 200 mg/24h;
- •Light chain multiple myeloma without measurable M protein in serum or urine: Involved serum free light chain (sFLC) ≥ 100 mg/L and abnormal serum κ/λ free light chain ratio；
- •Serum M- protein, urine M- protein, or involved sFLC not meeting above criteria but bone marrow plasma cell percentage ≥30%;
- •Subjects with primary plasma cell leukemia: peripheral blood plasma cell percentage≥5%at screening;
- •ECOG score of 0 or 1;
- •Estimated life expectancy ≥12 weeks;
- •Subjects must have adequate organ function and meet all of the following laboratory test results prior to enrollment:
- •Blood routine: absolute neutrophil count (ANC) ≥ 1×10^9/L (support with growth factor is allowed, but must not have received support treatment within 7 days before the laboratory test); Absolutely lymphocyte count (ALC) ≥0.3×10^9/L; Platelets ≥50×10^9/L (must not have received platelet transfusion support within 7 days before the laboratory test); Hemoglobin ≥60 g/L(must not have received red blood cell [RBC] transfusion within 7 days before the laboratory test);
- •Liver function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤2.5× Upper limit of normal value (ULN); Serum total bilirubin ≤1.5 ×ULN;
- •Renal function: creatinine clearance (CrCl) calculated by Cockcroft-Gault formula ≥ 40 ml/min;
- •Coagulation function: fibrinogen ≥ 1.0g /L; Activated partial thromboplastin time (aPTT) ≤1.5× ULN, Pro thrombin time (PT) ≤1.5× ULN;
- •Blood oxygen saturation(SaO2) >91%;
- •Left ventricular ejection fraction (LVEF) ≥ 50%;
- •Subjects agree to take effective measures or drug contraceptive measures (excluding safe period contraception) after signing the ICF and within one year after CAR-T cell infusion;
- •Subjects must sign an informed consent approved by the Ethics Committee before starting any screening procedures.
排除标准
- •Subjects who are known to have Graft-Versus-host disease (GVHD) or need long-term immunosuppressive therapy;
- •Subjects have received an autologous hematopoietic stem cell transplantation (auto-HSCT) within 12 weeks before leukapheresis or have a previous history of two times of auto-HSCT or previous history of an allogeneic hematopoietic stem cell transplantation (allo-HSCT);
- •Received targeted plasma cell therapy within 3 months before leukapheresis, or previous cell therapy products can still be detected in peripheral blood.
- •Subjects have received any anti-tumor treatment as follows, prior to leukapheresis:
- •Monoclonal antibody for multiple myeloma or plasma cell leukemia within 21 days, or;
- •Cytotoxic chemotherapy or proteasome inhibitors within 14 days, or;
- •Immunomodulators within 7 days, or;
- •Received other anti-cancer therapy within 14 days or at least 5 half-lives
- •Subjects require long-term use of glucocorticoids (defined as prednisone or equivalent > 20 mg/day) at a therapeutic dose during the study, physiologic replacement, topical, and inhaled steroids are permitted, nevertheless.
- •Subjects with hypertension that cannot be controlled by medication;
- •Sever cardiac disease including but not limited to unstable angina pectoris, myocardial infarction (within 6 months prior to screening), cardiac failure congestive (New York Heart Association [NYHA] class ≥ III), severe arrhythmia;
- •Unstable systemic disease as judged by the investigator: including but not limited to severe liver, renal, or metabolic disease requiring drug therapy ;
- •Subjects has prior history of malignancies, other than MM and plasma cell leukemia within 5 years before screening, with the exception of radical carcinoma in situ of the cervix, basal cell carcinoma or squamous cell carcinoma of skin, localized cancer of prostate after radical prostatectomy, ductal carcinoma in situ of breast after radical mastectomy, or papillary thyroid carcinoma after radical thyroidectomy;
- •Subjects with a history of organ transplantation;
- •Subjects with suspected or known central nervous system (CNS) involvement with myeloma;
- •Subjects with history of major surgery within 2 weeks prior to leukapheresis or planned to have surgery within 2 weeks after study treatment (except for subjects who were planned to have local anesthesia);
- •Treated with other investigational products within 1 month prior to leukapheresis;
- •Subjects have uncontrolled systemic fungal, bacterial, viral or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antimicrobial treatment) or requiring IV antimicrobials for management;
- •Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with detectable hepatitis B virus (HBV) DNA in peripheral blood; positive hepatitis C virus (HCV) antibody with positive HCV RNA in peripheral blood; positive human immunodeficiency virus (HIV) antibody; positive cytomegalovirus (CMV) DNA; Syphilis toluidine red unheated serum test (TRUST) and treponemal particle agglutination test (TPPA) were positive;
- •Pregnant or breastfeeding women;
- •Subjects have psychiatric disorders, conscious disorders, or central nervous system diseases;
- •Any condition for which, at the discretion of investigators, participation would not be in the best interest of the subject.
研究组 & 干预措施
RD140 injection
Experimental
subjects will receive a single infusion of Fully Human Anti-BCMA/GPRC5D Chimeric Antigen Receptor T Cells with does of 1-6×10^5 CAR T cells/kg.
干预措施: CAR-T（RD140 injection） (Biological)
结局指标
主要结局
Adverse Events
时间窗: 2 years after CAR-T cell infusion
Type and incidence of adverse events (AEs)
次要结局
- Overall response rate (ORR)(Up to 2 years post RD140 infusion)
- Duration of Response (DOR)(Up to 2 years post RD140 infusion)
- Progression-free Survival (PFS)(Up to 2 years post RD140 infusion)
- Overall Survival (OS)(Through study completion，up to 15 years post RD140 infusion)
- Time to Response (TTR)(Up to 2 years post RD140 infusion)
- Time to Complete Response (TTCR)(Up to 2 years post RD140 infusion)
- Minimal Residual Disease (MRD)(Up to 2 years post RD140 infusion)
- Duration of MRD negativity(Up to 2 years post RD140 infusion)
- Pharmacokinetics - Cmax(Up to 2 years post RD140 infusion)
- Pharmacokinetics - Tmax(Up to 2 years post RD140 infusion)
- Pharmacokinetics - Area Under the Curve (AUC)(Up to 2 years post RD140 infusion)
- soluble BCMA levels(Up to 2 years post RD140 infusion)
- C-reactive protein (CRP)(Up to 3 months post RD140 infusion)
- Ferritin(Up to 3 months post RD140 infusion)
- Interleukin-6 (IL-6)(Up to 3 months post RD140 infusion)
研究者
Jin Lu, MD
Principal of Investigator
Peking University People's Hospital
相似试验
尚未招募
1 期
A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple MyelomaMultiple MyelomaNCT05698303Nanjing IASO Biotechnology Co., Ltd.12
Unknown
1 期
Assessment of TK006 in Patients With Breast Cancer-related Bone MetastasesBreast CancerNCT03239756Jiangsu T-Mab Biopharma Co.,Ltd40
已完成
2 期
Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple MyelomaMultiple MyelomaNCT05032820Medical College of Wisconsin40
已完成
1 期
A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid TumorsLocally Advanced/Metastatic HER2 Positive Solid TumorsNCT04257110Bliss Biopharmaceutical (Hangzhou) Co., Ltd117
已完成
1 期
Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C MutationAdvanced or Metastatic Solid TumorKRAS G12C MutationNCT06117371BeBetter Med Inc11